Equillium Inc. Common Stock (EQ)
Stock · NASDAQ · Health Care
$1.2as of 10/16/2026
Price chart
Active signals
EQ Signal Track Record
How signals performed across all stocks →What EQ's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -3.4% | 43% | September 30, 2026 |
| Bollinger Band Breakdown | 20 | -17.1% | 25% | September 16, 2026 |
| Bollinger Band Breakout | 20 | -0.5% | 50% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +27.9% | 60% | December 5, 2025 |
| Any 20-session window (baseline) | -3.9% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral del…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 14
Fundamentals
- 1-day range
- $1.28$1.38
- Market cap
- $134.04M
- P/E (trailing)
- —
- P/E (forward)
- -5.57
- EPS (trailing)
- $-0.32
- Dividend yield
- —
- Beta
- 2.07
- Avg. volume
- 545.4K
How Equillium Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 27, 2025 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Equillium Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EQEquillium Inc. Common Stock$1.19▼ 9.85%Market cap $134.04MP/E —$0.76$3.54
- HURATuHURA Biosciences Inc. Common Stock$1.76▼ 3.83%Market cap $134.69MP/E —$0.41$3.43
- VTVTvTv Therapeutics Inc. Class A Common Stock$26.54▼ 3.81%Market cap $136.33MP/E 55.59$19.5$44
- CNTBConnect Biopharma Holdings Limited Ordinary Shares$0.906▲ 0.00%Market cap $137.89MP/E —$0.8501$3.82
- UNCYUnicycive Therapeutics Inc. Common Stock$3.36▼ 6.41%Market cap $138.33MP/E —$3.56$8.74
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
- SPRBSpruce Biosciences Inc. Common Stock$39.65▼ 4.39%Market cap $127.76MP/E —$38.06$179.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EQ Equillium Inc. Common Stock | $134.04M | — | $1.19 | ▼ 9.85% | $0.76$3.54 |
| HURA TuHURA Biosciences Inc. Common Stock | $134.69M | — | $1.76 | ▼ 3.83% | $0.41$3.43 |
| VTVT vTv Therapeutics Inc. Class A Common Stock | $136.33M | 55.59 | $26.54 | ▼ 3.81% | $19.5$44 |
| CNTB Connect Biopharma Holdings Limited Ordinary Shares | $137.89M | — | $0.906 | ▲ 0.00% | $0.8501$3.82 |
| UNCY Unicycive Therapeutics Inc. Common Stock | $138.33M | — | $3.36 | ▼ 6.41% | $3.56$8.74 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
| SPRB Spruce Biosciences Inc. Common Stock | $127.76M | — | $39.65 | ▼ 4.39% | $38.06$179.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6benzinga · 10/12/2026
- Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology ConferenceYahoo · 10/6/2026
- Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504Yahoo · 10/5/2026
- Equillium Announces Poster Presentations at the 7th International AHR ConferenceYahoo · 9/29/2026
- Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504Yahoo · 9/27/2026
- Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation ForumYahoo · 9/16/2026
Insider Activity
Insider Actions →- Zedelmayer Christine · June 5, 2026 · Option Exercise14.6K @ $0.785
- Zedelmayer Christine · June 5, 2026 · Sale14.6K @ $2.93
- Connelly Stephen · June 5, 2026 · Sale31.0K @ $2.94
- Connelly Stephen · June 4, 2026 · Sale200.0K @ $3.16
- Zedelmayer Christine · May 28, 2026 · Option Exercise7.3K @ $0.73
- Zedelmayer Christine · May 28, 2026 · Sale30.2K @ $2.98
- Zedelmayer Christine · May 28, 2026 · Sale55.6K @ $2.7
- McDermott Charles Douglas · May 28, 2026 · Grant70.0K
- Troupin Barbara · May 28, 2026 · Grant70.0K
- Pruzanski Mark · May 28, 2026 · Grant70.0K
- Daniel Bradbury · May 28, 2026 · Grant70.0K
- Martha J. Demski · May 28, 2026 · Grant70.0K
- Zedelmayer Christine · May 28, 2026 · Sale200 @ $2.71
- Tom Penny · May 28, 2026 · Option Exercise65.0K @ $0.785
- Tom Penny · May 28, 2026 · Sale65.0K @ $2.95
Institutional Ownership
March 31, 2026
- Total shares held
- 40.45M
- Total value held
- $80.87M
- Institutional holders
- 48
- Unknown6.49M
- Unknown5.33M
- Unknown4.45M
- Unknown3.73M
- Unknown3.50M
- Unknown3.35M
- Unknown3.10M
- Unknown1.78M
- Unknown1.64M
- Unknown1.50M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Equillium Targets Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium announced plans to start Phase I trials for its ulcerative colitis drug EQ504 in Q4. This milestone could affect the company’s future revenue if the trial is successful. The announcement comes while the stock trades near its 13‑touch support level at $2.20 and has a low RSI of 30.5.
Equillium Targets Q4 Phase I Start for Ulcerative Colitis Drug EQ504. Equillium announced plans to start Phase I trials for its ulcerative colitis drug EQ504 in Q4. This milestone could affect the company’s future revenue if the trial is successful. The announcement comes while the stock trades near its 13‑touch support level at $2.20 and has a low RSI of 30.5.